Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. (2021)

First Author: Heaney LG
Attributed to:  United Kingdom Refractory Asthma Stratification Programme (RASP-UK) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(20)30397-0

PubMed Identifier: 32916135

Publication URI: http://europepmc.org/abstract/MED/32916135

Type: Journal Article/Review

Volume: 9

Parent Publication: The Lancet. Respiratory medicine

Issue: 1

ISSN: 2213-2600